Molecular Partners AG (XSWX:MOLN) 3-Year Book Growth Rate : 13.40% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG 3-Year Book Growth Rate?

Molecular Partners AG's Book Value per Share for the quarter that ended in Dec. 2023 was CHF5.37.

During the past 12 months, Molecular Partners AG's average Book Value per Share Growth Rate was -17.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was 13.40% per year. During the past 5 years, the average Book Value per Share Growth Rate was 11.70% per year. During the past 10 years, the average Book Value per Share Growth Rate was -1.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Molecular Partners AG was 38.30% per year. The lowest was -27.40% per year. And the median was -9.00% per year.

Competitive Comparison of Molecular Partners AG's 3-Year Book Growth Rate

For the Biotechnology subindustry, Molecular Partners AG's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's 3-Year Book Growth Rate falls into.

Molecular Partners AG 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Molecular Partners AG (XSWX:MOLN) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Molecular Partners AG 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.